Hannah Dry
AstraZeneca (United States)(US)AstraZeneca (Germany)(DE)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research, Chronic Lymphocytic Leukemia Research, Quinazolinone synthesis and applications
Most-Cited Works
- → Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases(2013)213 cited
- → Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial(2023)188 cited
- → Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors(2013)160 cited
- → BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).(2021)106 cited
- → Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel(2014)99 cited
- → Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)(2022)49 cited
- → TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy(2024)36 cited
- → BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).(2022)26 cited
- → O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial(2022)15 cited
- → Optimization of a series of potent, selective and orally bioavailable SYK inhibitors(2020)9 cited